



CNR2 rs2229579 and COMT Val158Met variants, but not CNR2 rs2501432, IL-17 rs763780 and UCP2 rs659366, contribute to susceptibility to substance use disorder in the Turkish population

Selin Kurnaz, Ahmet Bulent Yazici, Ayse Feyda Nursal, Pinar Cetinay Aydin, Ayca Ongel Atar, Nazan Aydin, Zeliha Kincir & Sacide Pehlivan

To cite this article: Selin Kurnaz, Ahmet Bulent Yazici, Ayse Feyda Nursal, Pinar Cetinay Aydin, Ayca Ongel Atar, Nazan Aydin, Zeliha Kincir & Sacide Pehlivan (2019): CNR2 rs2229579 and COMT Val158Met variants, but not CNR2 rs2501432, IL-17 rs763780 and UCP2 rs659366, contribute to susceptibility to substance use disorder in the Turkish population, *Psychiatry and Clinical Psychopharmacology*, DOI: [10.1080/24750573.2019.1688030](https://doi.org/10.1080/24750573.2019.1688030)



© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group



Published online: 03 Dec 2019.



Submit your article to this journal



View related articles



View Crossmark data

CNR2 rs2229579 and COMT Val158Met variants, but not CNR2 rs2501432, IL-17 rs763780 and UCP2 rs659366, contribute to susceptibility to substance use disorder in the Turkish population

Selin Kurnaz^a, Ahmet Bulent Yazici  ^b, Ayse Feyda Nursal  ^c, Pinar Cetinay Aydin  ^d, Ayca Ongel Atar^d, Nazan Aydin  ^d, Zeliha Kincir ^d and Sacide Pehlivan^a

^aDepartment of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey; ^bDepartment of Psychiatry, Sakarya University Training and Research Hospital, Sakarya, Turkey; ^cDepartment of Medical Genetics, Faculty of Medicine, Hittit University, Corum, Turkey; ^dDepartment of Psychiatry, Bakirkoy Mazhar Osman Training and Research Hospital for Psychiatry, Istanbul, Turkey

ABSTRACT

OBJECTIVE: Substance use disorders (SUD) are among the most important public health problems throughout the world. We investigated whether COMT (Val108/158Met), CNR2 (rs2501432 and rs2229579), UCP2 (rs659366), and IL-17 (rs763780) gene variants were associated with SUD and its clinical parameters in a Turkish population.

METHODS: We conducted a case-control study among 136 subjects with SUD and 100 healthy controls. Six variants were analysed by the PCR-RFLP method.

RESULTS: The CNR2 rs2229579 T/T genotype and T allele increased in SUD groups than controls while the C/C genotype and C allele were more prevalent in the control group compared to the SUD group ($p = 0.000$ and $p = 0.001$, respectively). The COMT Val108/158Met Val/Val genotype and Val allele were significantly associated with polysubstance abuse ($p < 0.05$). There was no significant difference between the SUD group and control group regarding genotype and allele frequencies of COMT (Val108/158Met), CNR2 (rs2501432), UCP2 (rs659366) and IL-17 (rs763780) variants.

CONCLUSIONS: This is the first study that discussed the relation of these variants and SUD patients in the Turkish population. The results of the analysis indicated that the CNR2 rs2229579 variant has an effect on susceptibility to SUD, suggesting that this variant might play a role in the physiopathology of SUD. The COMT Val108/158Met variant might be an important factor affecting polysubstance use.

ARTICLE HISTORY

Received 9 August 2019

Accepted 8 October 2019

KEYWORDS

Substance use disorder; variant; PCR-RFLP; COMT; CNR2; UCP2; IL-17

Introduction

A "substance" refers to any psychoactive compound that can lead to health and social problems, such as addiction. These substances may be legal or illicit. Substance use disorders (SUDs) manifest a global threat to public health and bear a devastating social and economic impact on individuals as well as their families. According to DSM-V [1], SUD are classified depending on the types of pathological behaviours and four classes of criteria (impaired control, social impairment, risky use, and pharmacological criteria). The mechanism of addiction formation has distinct steps: the beginning of substance use, the transition from trying out to regular use, and the real development of addiction. Environmental factors such as friend pressure, parental monitoring, and the availability of a substance play an important role in the initial attempt to drink, smoke, or take illegal drugs. Following the first step, the transition from regular substance use to dependence varies among the individuals and is largely subject to genetic control [2]. The role of genetic factors in the development of alcohol and other drug addiction has been

shown by many family, twin, and adoption studies in general population samples.

Catechol-O-methyltransferase (COMT) is an enzyme found all over the mammalian central nervous system which breaks down the catecholamine neurotransmitters dopamine, epinephrine, and norepinephrine. A common G-to-A transition in exon 4 of the COMT gene, causing a valine (val)-to-methionine (met) substitution at the amino acid position 108 or 158 (depending on the splice variant), results in a four-fold reduction in enzyme activity in met homozygotes, whereas heterozygotes manifest intermediate activity [3]. The endocannabinoid system plays a role in susceptibility to substance abuse. There are two well-defined cannabinoid receptors (CNRs), CNR1/CB1 and CNR2/CB2, that mediate endocannabinoid signalling [4]. CNR2 has been classically defined as the peripheral cannabinoid receptor because CNR2 is expressed principally in some peripheral and immune cells [5]. Uncoupling protein 2 (UCP2) is a member of an anion-carrier protein family found in the mitochondrial inner membrane. In the central nervous

system, mammalian *UCP2* mRNA and protein expression occurs at highest levels in regions that could be described as high-risk for stress [6]. The Interleukin 17 (IL-17 or IL-17A) is a fundamental pro-inflammatory cytokine that is primarily released from T cells and is now believed to be the defining cytokine of a recently discovered new subset of T-helper cells, Th17 [7]. New studies have reported that cells of the central nervous system also express IL-17.

Therefore, in this study, we investigated whether COMT (Val108/158Met rs4680), CNR2 (rs2501432, 315A/G), CNR2 (rs2229579, 1073C/T), UCP2 (rs659366, -866A/G) and IL-17 (rs763780, -7488A/G) gene variants were associated with SUD and its clinical parameters in a Turkish population.

Methods

Study population

This case-control study included 136 subjects with SUD (female/male: 4/132) and 100 age-matched healthy controls (female/male: 52/48). The subjects with SUD were selected from among the individuals with a positive urine test in the Department of Psychiatry, Bakirkoy Research and Training Hospital for Psychiatry Hospital, Istanbul Turkey and Department of Psychiatry, Sakarya University Training and Research Hospital, Sakarya Turkey [8]. The healthy control group was similar in terms of age and sex distribution; with 100 healthy individuals who did not have a personal history of any psychiatric disorder and chronic use of any drugs. All members of the patient and control groups were of the same ethnic origin, declared as Turkish ethnicity. Informed written consent was obtained from all the subjects. This study protocol was approved by the Local Ethics Committees of Istanbul University, Faculty of Medicine (2015/1945), in accordance with the ethical standard for human experimentation established by the Declaration of Helsinki.

Genotyping

All study participants provided 2 ml of venous blood from the antecubital vein, which was added to 1%

ethylenediaminetetra-acetic acid tubes for DNA isolation. DNA was extracted from peripheral blood samples using a salting-out procedure [9]. The genotypes of COMT (Val108/158Met), CNR2 (rs2501432 and rs2229579), UCP2 (rs659366), and IL-17 (rs763780) gene variants were determined by the PCR-RFLP method as described by previous methods [10-13]. Primer sequences used and PCR conditions in the study are shown in Table 1.

Statistical analysis

Statistical analyses were done by SPSS (Statistical Package for Social Sciences, Chicago, IL, USA) 22.0 package program. Differences between patients and controls in distribution of genotype were compared using χ^2 -test or Fisher's exact test as appropriate. The relative risk associated with rare alleles was estimated as an odds ratio (OR) with a 95% confidence interval (CI). All *p* values ≤ 0.05 were accepted as statistically significant.

Results

A total of 136 patients with SUD and 100 controls were included in the present study. The mean age of the SUD group and control group were 29.17 ± 7.99 and 31.01 ± 10.77 years, respectively. Gender, age, marriage, education, working condition, smoking, and alcohol use of SUD patients were analysed. The baseline and demographic features of the study participants are presented in Table 2. A significant difference in the gender, education status, smoking, and alcohol use was observed between the patient and the control group. The majority of the patient group consisted of males (*p* < 0.001). Education level was lower in the SUD group than control (*p* < 0.001). Smoking and alcohol use were increased in the SUD group than control (*p* < 0.001 and *p* < 0.001, respectively).

We also evaluated characteristics of SUD. These characteristics are presented in Table 3. The allele and genotype frequencies of CNR2 rs2229579 variant in the SUD group and control group are summarized in Table 4. CNR2 rs2229579 T/T genotype increased in SUD groups than controls, while the C/C genotype

Table 1. Primer sequences and PCR conditions of the gene variants.

Variants	Primer sequences	Annealing temperature-Cycle number	Restriction enzyme	References
COMT Val108Met	F: 5'-TCG TGG ACG CCG TGA TTC AGG-3' R: 5'-AGG TCT GAC AAC GGG TCA GGC-3'	55°C/35	<i>Nla</i> III	[9]
COMT Val158Met	F: 5'-ACT GTG GCT ACT CAG CTG TG-3' R: 5'-CCT TTT TCC AGG TCT GAC AA-3'	58°C/35	<i>Nla</i> III	[9]
CNR2 rs2501432	F: 5'- GAA CAG GTA TGA GGGCTT TCG GCG G-3' R: 5'-CAC CCC ATG GAG GAA TGC TGG GTG ACA G-3'	67°C/35	<i>Msp</i> I	[10]
CNR2 rs2229579	F: 5'-CTC TGC CCA TCA CTG CCG G-3' R: 5'-GGG TCC GTG TCT AGG TGT CTG G-3'	57°C/35	<i>Ban</i> II	[10]
UCP2 rs659366	F: 5'-CAC GCT TCT GCC AGG AC-3' R: 5'-AGG CGT CAG GAG ATG GAC CG-3'	65°C/35	<i>Mlu</i> I	[12]
IL-17 rs659366	F: 5'-GTG TAG GAA CTT GGG CTG CAT CAA T-3' R: 5'-AGC TGG GAA AAA CAA AC-3'	52.2°C/35	<i>Nla</i> III	[11]

Table 2. Baseline and demographics features of the patients and controls.

	SUD group n (%)	Control group n (%)	p	OR
Age	29.17 ± 7.99	31.01 ± 10.77		
Gender				
Male	132 (97.1)	48 (48.0)	<0.001	35.75
Female	4 (2.9)	52 (52.0)		
Marriage			0.891	0.938
Single	71 (56.3)	55 (57.9)		
Married	55 (43.7)	40 (42.1)		
Education				
Illiterate	9 (7.1)	0 (0)	<0.001	
Primary school	26 (20.5)	8 (8.4)		
Secondary school	64 (50.4)	4 (4.2)		
High school	26 (20.5)	8 (8.4)		
College	2 (1.6)	75 (78.9)		
Working condition			0.498	1.222
Working	66 (52.4)	45 (47.4)		
At rest	60 (47.6)	50 (52.6)		
Smoking			<0.001	
Yes	125 (97.7)	0 (0)		
No	3 (2.3)	100 (100)		
Alcohol use			<0.001	
Yes	57 (44.5)	0 (0)		
No	71 (55.5)	100 (100)		

Note: The results that are statistically significant are shown in boldface.

was higher in the control group compared to the SUD group ($p = 0.000$). Also, the CNR2 rs2229579 T allele was more prevalent in the SUD group than the patient group ($p = 0.000$).

Genotype and allele frequencies of COMT (Val108/158Met), CNR2 (rs2501432), UCP2 (rs659366), and IL-17 (rs763780) were not statistically different between patients and healthy controls (data not shown).

Table 3. Characteristics of substance use.

		n (%)
Prevalent Substance	Synthetic cannabinoid	80 (58.8)
	Cannaboid	27 (19.9)
	Heroin	21 (15.4)
Usage	Ecstasy	8 (5.9)
	Inhalation	110 (88.0)
	Eat/drink	9 (7.2)
	Injection	6 (4.8)
Frequency of usage	Everyday	66 (52.0)
	Once a week	61 (48.0)
Polysubstance usage	Yes	66 (52.0)
	No	61 (48.0)
Secondary substance	Ecstasy	22 (34.9)
	Cannaboid	21 (33.3)
	Synthetic cannabinoid	9 (14.3)
	Cocaine	6 (9.5)
	Heroin	2 (3.2)
	Volatile substance	2 (3.2)
	Methamphetamine	1 (1.6)
Psychosis findings	Yes	65 (49.2)
	No	67 (50.8)
Psychosis	Substance-related psychosis	43 (78.2)
	Other	18 (21.8)
Suicide attempt	Yes	32 (25.0)
	No	96 (75.0)
Self-mutilation	Yes	32 (25.0)
	No	96 (75.0)
Family history of psychosis	Yes	25 (20.5)
	No	97 (79.5)
Family history of smoking	Yes	102 (80.3)
	No	25 (19.7)
Alcohol usage in family	Yes	38 (30.9)
	No	85 (69.1)
Substance usage in family	Yes	13 (10.4)
	No	112 (9.6)

Table 4. Genotype and allele frequencies of CNR2 rs2229579 variant.

CNR2 rs2229579	SUD group n:136 (%)	Control group n:100 (%)	p	OR
Genotypes				
T/T*	38 (27.9)	2 (2.0)	0.000	OR1 = 15.69
T/C	46 (33.8)	38 (38.0)		OR2:21.92
C/C	52 (38.2)	60 (60.0)		
Alleles				
T	122 (44.9)	42 (21)	0.000	3.059
C	150 (55.1)	158 (79)		

Note: Data were analysed by χ^2 test. The results that are statistically significant are shown in boldface.

*Reference category for odds calculation.

Additionally, we compared whether polysubstance usage was associated with frequencies of genotype and allele of these variants. There was a statistically significant difference between patients and controls regarding genotype and allele frequencies of the COMT Val108/158Met variant (Table 5). COMT Val108Met and Val158Met Val/Val genotypes were more prevalent in the polysubstance user group than the non-polysubstance user group, while Met/Met genotype was higher in the non-polysubstance group user compared to the polysubstance user group (respectively, $p = 0.033$, $p = 0.013$). Also, COMT Val108Met and Val158Met Val alleles were associated with polysubstance use ($p = 0.013$ and $p = 0.001$, respectively).

Additionally, we investigated the relationship between age at onset for SUD and SUD-related psychosis. SUD-related psychosis was significantly associated with age of onset for SUD. SUD-related psychosis was more common in the subjects with age of onset ≤ 18 ($p = 0.001$, OR: 12.95) (Table 6).

Discussion

SUDs are chronic relapsing psychiatric disorders manifested by the compulsive and dyscontrolled use of a

Table 5. Genotype and allele frequencies of COMT gene variants according to polysubstance usage.

COMT Val 108Met	Polysubstance usage		p	OR
	Yes n (%)	No n (%)		
Genotypes				
Val/Val*	25 (38.5)	15 (24.6)	0.033	OR1:1.464
Val/Met	33 (50.8)	29 (47.5)		OR2:4.047
Met/Met	7 (10.8)	17 (27.9)		
Alleles				
Val	83 (63.8)	59 (48.4)	0.013	1.885
Met	47 (36.2)	63 (51.6)		
COMT Val158Met	Polysubstance Usage			
Genotypes				
	Yes n (%)	No n (%)		
Val/Val*	35 (53.0)	17 (28.3)	0.013	OR1:2.433
Val/Met	22 (33.3)	26 (43.3)		OR2:3.888
Met/Met	9 (13.6)	17 (28.3)		
Alleles				
Val	92 (69.7)	60 (50)	0.001	OR:2.300
Met	40 (30.3)	60 (50)		

Note: Data were analysed by χ^2 test. The results that are statistically significant are shown in boldface.

*Reference category for odds calculation.

Table 6. The relationship between onset age of SUD and SUD-related psychosis.

	Onset age of SUD			<i>p</i>
	≤18 <i>n</i> (%)	>18 <i>n</i> (%)		
SUD-related psychosis	34 (91.9)	7 (46.7)	0.001	
Other	3 (8.1)	8 (53.3)		

Note: The results that are statistically significant are shown in boldface.

drug or activity, resulting in maladaptive and destructive outcomes. When analysing the risk factors for addictions, it is crucial to underline the biological events that are involved in these activities and to develop drugs that can hinder the molecular mechanisms to prevent and to treat the addictions. Studies have reported the important role of heritable impacts on individual differences in addiction. Twin studies suggested that genetic factors account for more than half of the cases. The genetic impact for addictions is not related to a contribution of a single gene; however, it is the result of the interaction of different genes that along with environment factors stimulate a condition of "susceptibility" to the disorder. The substance use and behaviours will be represented in the brain but, more significantly, drug use modifies the brain chemistry in ways that keep and potentially enhance consumption [14]. Addictive drugs cause neuronal changes in cortical and basal ganglia structures, as well as in the mesocorticolimbic dopamine system, resulting in alterations of synaptic reorganization and function [15]. Dopaminergic brain systems have been implicated in drug reward [16], hence the genes that have a role in these circuits are likely candidates for susceptibility to SUDs.

COMT is an enzyme that plays a role in metabolism of various catecholamine neurotransmitters, such as dopamine and epinephrine. The *COMT* gene is 27.22 kb in length, and is found on chromosome 22q11.2 [17]. A common non-synonymous single-nucleotide polymorphism (rs4680) changes the 158th amino acid residue of the membrane-bound isoform (or 108th amino acid of the soluble form) from valine (Val) to methionine (Met). Chen et al. demonstrated that Val/Val homozygotes have higher stability than the Met/Met homozygotes, and COMT activity in Val/Val homozygotes is approximately 40% higher than in Met/Met homozygotes, while Val/Met heterozygotes have moderate enzyme activity [18]. Some studies reported that the Val158-Met variant plays a role in psychiatric phenotypes, such as schizophrenia and bipolar disorder [19,20], and reported that individuals with the high-activity COMT variant may have greater genetic vulnerability to drug abuse [21]. Serý et al. found a relationship between the Val158Met variant of the *COMT* gene and alcoholism in male subjects [22]. In different studies, it was found that *COMT* Val158Met variant

was associated with heroin [23], cocaine [24], methamphetamine [25], inhalant use [26]. In this study, although there was no association between patients and controls regarding genotype and allele frequencies of *COMT* (Val108/158Met), we found a significant association between *COMT* Val108/158Met variant and polysubstance use, with the Val allele (high activity) being over-represented in patients versus controls (Table 6).

The endocannabinoid system plays a role in the modulation of numerous physiological processes including neurotransmission, pain perception, appetite, and immune response. The discovery of an endocannabinoid physiological control system (EPCS) has resulted in the investigation of this system in the central nervous system and its possible involvement in mental disorders. It was shown that the variants of *CNR1* were linked with higher vulnerability to cannabis, alcohol, and drug addiction [27–29]. While *CNR1* has been widely investigated, only a few number of authors studied the role of *CNR2* in psychiatric disorders. *CNR2* receptors are chiefly found in the immune cells, however they have also been identified in some regions of the rat brain, such as cerebral cortex, striatum, amygdala, thalamus, cerebellum, spinal nucleus, olfactory nucleus, and hippocampus [30]. Further investigation searched whether cannabinoid CB2 receptor knockout (CB2KO) mice similarly showed a higher aggression compared with wild-type during the social interaction test and resident–intruder paradigm [31]. There are several association studies between *CNR2* variants gene and schizophrenia [11], eating disorders [32], depression [33], and alcoholism [34]. Okahisa et al. reported that the *CNR2* Q63R variant did not affect the risk of methamphetamine dependence and psychosis or the clinical phenotypes of methamphetamine psychosis in a Japanese population [4]. In this study, we found a significant difference between SUD patients and the control group regarding genotype and allele frequencies of the *CNR2* rs2229579 variant. *CNR2* rs2229579 TT genotype and T allele were associated with SUD compared to other genotypes and alleles, while *CNR2* rs2229579 CC genotype and C allele were higher in healthy control group than patients (Table 5).

UCPs are integral proteins found in the mitochondrial inner membrane and modulate the mitochondrial membrane potential by discharge of the proton gradient produced during oxidative phosphorylation and negatively regulate mitochondrial ATP synthesis. Their capacity to regulate the passage of protons and consequent proton gradient make uncoupling proteins crucial in controlling neuromodulation and neuroprotection. UCP2 and UCP3 can diminish the generation of superoxide radicals at complex I of the mitochondrial respiratory chain by decreasing the electrical potential across the inner mitochondrial membrane

the prevalence of some homozygous variants was low in groups and thus reduced the statistical power. Further studies are needed to replicate this. Second, although our patients were recruited from two centres, genotyping was not divided according to the centre. Another limitation of the study involves the fact that gene expressions have not been evaluated.

[35]. The neuroprotective effect of UCP2 has been shown by many studies in animals and cell cultures. Sullivan et al. reported that neurones from immature rat brains were more resistant to seizures compared to those from mature rat brain and that this was due to higher levels of mitochondrial uncoupling in those cells, associated with a higher expression of UCP2 [36]. Due to this significant functions, UCP variants were assessed often in some diseases including body composition and resting energy expenditure [37], energy metabolism [38], obesity [39], multiple sclerosis [40], diabetic neuropathy [41], and schizophrenia [42]. There is no study examining the relationship between UCP2 variants and dependence. In the present study, there was no significant association between UCP2 rs659366 variant and SUD.

To facilitate the therapeutic process in addiction, one of the difficulties is to define biological markers that could help in objectively determining the level of consumption, severity of addiction, degree of toxicity, and response to treatment in patients. Several studies have shown that abused drugs interact with the immune system and modify signalling and gene expression that occur in the immune response, and these effects contribute to different aspects of addiction [43]. Because the immune system modifies brain functions related to addiction and the concurrent participation of reward modulatory systems in psychiatric disorders, there is a possibility of establishing a link between inflammation, neuropsychiatric diseases, and addictive disorders. Moreira et al. demonstrated that there was a statistically significant increase in IL-6 and decrease in IL-10 serum levels between cocaine users and the control group [44]. Also, it was reported that IL-10-592C/A and IL-1 α -889 C/T variants were associated with alcoholism [45,46]. These results pointed to an inflammatory status associated with dependence.

The IL-17 family members are pro-inflammatory cytokines mainly released by T-helper 17 (Th17) cells. IL-17 gene variants have been found to be linked with numerous autoimmune diseases, such as asthma [47], celiac disease [48], and inflammatory bowel disease [49]. Reduced synthesis of IL-6, IL-12, IL-17A, IFN-gamma, and high levels of IL-13 cytokines due to ovalbumin stimulation in alcohol-consuming mice have also been reported [50]. In the present study, no statistically significant difference between patients and controls was found in the frequency of the evaluated genotype and allele frequencies of the IL-17 rs763780 variant.

In this study, we found that SUD-related psychosis was significantly associated with onset age of SUD. SUD-related psychosis was more prevalent in the subjects with onset of age ≤ 18 ($p = 0.001$) (Table 6).

This study has several limitations. The first limitation of this study was the small sample size. Therefore,

Conclusion

Studies have been carried out over the last decades to find out the neurobiological mechanisms underlying drug addiction. To the best of our knowledge, this is the first study investigating the association between these variants and SUD in a Turkish population. This study provides insights into the CNR2 rs2229579 variant that is thought to be risk factor of substance use. Also, COMT Val108/158Met variants might be important factors affecting the polysubstance usage. As a conclusion, we can suggest that DNA research in humans can contribute to help define the substances and systems in the brain which are associated with addiction and to determine whether or not certain individuals are susceptible to substance use. Further studies are needed to understand clearly how genetic variants influence the development of vulnerability to addiction.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This study was supported by Istanbul University BAP thesis project (No: TYL-2016-20431) support programme.

ORCID

Ahmet Bulent Yazici  <http://orcid.org/0000-0001-5631-3100>
 Ayse Feyda Nursal  <http://orcid.org/0000-0001-7639-1122>
 Pinar Cetinay Aydin  <http://orcid.org/0000-0002-1605-2724>
 Nazan Aydin  <http://orcid.org/0000-0003-3232-7713>

References

- [1] American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.
- [2] Loftis JM, Huckans M. Substance use disorders: psychoneuroimmunological mechanisms and new targets for therapy. *Pharmacol Ther*. 2013;139:289–300.
- [3] Havelka Mestrovic A, Tudor L, Nikolac Perkovic M, et al. Significant association between catechol-O-methyltransferase (COMT) Val^{158/108}Met polymorphism and cognitive function in veterans with PTSD. *Neurosci Lett*. 2018;666:38–43.
- [4] Okahisa Y, Kodama M, Takaki M, et al. Association study of two cannabinoid ReceptorGenes, CNR1 and

CNR2, with methamphetamine dependence. *Curr Neuropharmacol.* **2011**;9:183–189.

[5] Berdyshev EV. Cannabinoid receptors and the regulation of immune response. *Chem Phys Lipids.* **2000**;108:169–190.

[6] Normoyle KP, Kim M, Farahvar A, et al. The emerging neuroprotective role of mitochondrial uncoupling protein-2 in traumatic brain injury. *Transl Neurosci.* **2015**;6:179–186.

[7] Weaver CT, Harrington LE, Mangan PR, et al. Th17: An effector CD4 T cell lineage with regulatory T cell ties. *Immunity.* **2006**;24:677–688.

[8] Blandino V, Wetzel J, Kim J, et al. Oral fluid vs. urine analysis to monitor synthetic cannabinoids and classic drugs recent exposure. *Curr Pharm Biotechnol.* **2017**;18:796–805.

[9] Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from nucleated cells. *Nucleic Acids Res.* **1988**;16:1215–1215.

[10] Bialecka M, Drożdżik M, Kłodowska-Duda G, et al. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. *Acta Neurol Scand.* **2004**;110:260–266.

[11] Tong D, He S, Wang L, et al. Association of single-nucleotide polymorphisms in the cannabinoid receptor 2 gene with schizophrenia in the Han Chinese population. *J Mol Neurosci.* **2013**;51:454–460.

[12] Paradowska-Gorycka A, Wojtecka-Lukasik E, Trefler J. Association between IL-17F gene polymorphisms and susceptibility to and severity of rheumatoid arthritis (RA). *Scand J Immunol.* **2010**;72:134–141.

[13] Sesti G, Cardellini M, Marini MA, et al. A common polymorphism in the promotor of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects. *Diabetes.* **2003**;52:1280–1283.

[14] Altman JE, Glautier S BJ, et al. The biological, social and clinical bases of drug addiction: commentaryary and debate. *Psychopharmacology (Berl).* **1996**;125:285–245.

[15] Lüscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. *Neuron.* **2011**;69:650–663.

[16] Juárez Olgún H, Calderón Guzmán D, Hernández García E, et al. The role of dopamine and its dysfunction as a consequence of oxidative stress. *OxidMed Cell Longev.* **2016**;2016:9730467.

[17] González-Castro TB, Hernández-Díaz Y, Juárez-Rojop IE, et al. The role of COMT gene Val108/158Met polymorphism in suicidal behavior: systematic review and updated meta-analysis. *Neuropsychiatr Dis Treat.* **2018**;14:2485–2496.

[18] Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, enzyme activity in postmortem human brain. *Am J Hum Genet.* **2004**;75:807–821.

[19] González-Castro TB, Hernández-Díaz Y, Juárez-Rojop IE, et al. The role of a catechol-o-methyltransferase (COMT) Val158Met genetic polymorphism in schizophrenia: a systematic review and updated meta-analysis on 32,816 subjects. *Neuromolecular Med.* **2016**;18:216–231.

[20] Burdick KE, Funke B, Goldberg JF, et al. COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. *Bipolar Disord.* **2007**;9:370–376.

[21] Vandenberghe DJ, Rodriguez LA, Miller IT, et al. High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. *Am J Med Genet.* **1997**;74:439–442.

[22] Serý O, Didden W, Mikes V, et al. The association between high-activity COMT allele and alcoholism. *Neuro Endocrinol Lett.* **2006**;27:231–235.

[23] Horowitz R, Kotler M, Shufman E, et al. Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. *Am J Med Genet.* **2000**;96:599–603.

[24] Lohoff FW, Weller AE, Bloch PJ, et al. Association between the catechol-O-methyltransferase (COMT) Val158Met polymorphism and cocaine dependence. *Neuropsychopharmacology.* **2008**;33:3078–3084.

[25] Hosák L, Libiger J, Cizek J, et al. The COMT Val158Met polymorphism is associated with novelty seeking in Czech methamphetamine abusers: preliminary results. *Neuro Endocrinol Lett.* **2006**;27:799–802.

[26] Intharachutia W, Ittiwit R, Listman J, et al. Polymorphism of COMT Val158Met is associated with inhalant use and dependence: a Thai substance dependence treatment cohort. *Asian Biomed.* **2012**;6 (4):549–556.

[27] Hartman CA, Hopfer CJ, Haberstick B, et al. The association between cannabinoid receptor 1 gene (CNR1) and cannabis dependence symptoms in adolescents and young adults. *Drug Alcohol Depend.* **2009**;104:11–16.

[28] Proudnikov D, Kroslik T, Sipe JC, et al. Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1. *Pharmacogenomics J.* **2010**;10:232–242.

[29] Zuo L, Kranzler HR, Luo X, et al. CNR1 variation modulates risk for drug and alcohol dependence. *Biol Psychiatry.* **2007**;62:616–626.

[30] Kolla NJ, Mishra A. The endocannabinoid system, aggression, and the violence of synthetic cannabinoid use, borderline personality disorder, antisocial personality disorder, and other psychiatric disorders. *Front Behav Neurosci.* **2018**;12:41.

[31] Rodríguez-Arias M, Navarrete F, Blanco-Gandia MC, et al. Role of CB2 receptors in social and aggressive behavior in male mice. *Psychopharmacology (Berl).* **2015**;232:3019–3031.

[32] Ishiguro H, Carpio O, Horiuchi Y, et al. A nonsynonymous polymorphism in cannabinoid CB2 receptor gene is associated with eating disorders in humans and food intake is modified in mice by its ligands. *Synapse.* **2010**;64:92–96.

[33] Minocci D, Massei J, Martino A, et al. Genetic association between bipolar disorder and 524A > C (Leu133Ile) polymorphism of CNR2 gene, encoding for CB2 cannabinoid receptor. *J Affect Disord.* **2011**;134:427–430.

[34] Ishiguro H, Iwasaki S, Teasenfitz L, et al. Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. *Pharmacogenomics J.* **2007**;7:380–385.

[35] Laskowski KR, Russell RR. Uncoupling proteins in heart failure. *Curr Heart Fail Rep.* **2008**;5:75–79.

[36] Sullivan PG, Dubé C, Dorenbos K, et al. Mitochondrial uncoupling protein-2 protects the immature brain from excitotoxic neuronal death. *Ann Neurol.* **2003**;53:711–717.

- [37] Yanovski JA, Diament AL, Sovik KN, et al. Associations between uncoupling protein. Associations between uncoupling protein 2, body composition, and resting energy expenditure in lean and obese African American, white, and Asian children. *Am J Clin Nutr.* **2000**;71:1405–1420.
- [38] Kovacs P, Ma L, Hanson RL, et al. Genetic variation in UCP2 (uncoupling protein-2) is associated with energy metabolism in Pima Indians. *Diabetologia.* **2005**;48: 2292–2295.
- [39] Ochoa MC, Santos JL, Azcona C, et al. GENOI members. Association between obesity and insulin resistance with UCP2-UCP3 gene variants in Spanish children and adolescents. *Mol Genet Metab.* **2007**;92:351–358.
- [40] Vogler S, Goedde R, Mitterski B, et al. Association of a common polymorphism in the promoter of UCP2 with susceptibility to multiple sclerosis. *J Mol Med (Berl).* **2005**;83:806–811.
- [41] Yamasaki H, Sasaki H, Ogawa K, et al. Uncoupling protein 2 promoter polymorphism -866G/A affects peripheral nerve dysfunction in Japanese type 2 diabetic patients. *Diabetes Care.* **2006**;29:888–894.
- [42] Yasuno K A, Misumi S S, et al. Synergistic association of mitochondrial uncoupling protein (UCP) genes with schizophrenia. *Am J Med Genet B Neuropsychiatr Genet.* **2007**;144B:250–253.
- [43] Cui C, Shurtleff D, Harris RA. Neuroimmune mechanisms of alcohol and drug addiction. *Int RevNeurobiol.* **2014**;118:1–12.
- [44] Moreira FP, Medeiros JR, Lhullier AC, et al. Cocaine abuse and effects in the serum levels of cytokines IL-6 and IL-10. *Drug Alcohol Depend.* **2016**;158:181–185.
- [45] Marcos M, Pastor I, González-Sarmiento R, et al. Interleukin-10 gene polymorphism is associated with alcoholism but not with alcoholic liver disease. *Alcohol Alcohol.* **2008**;43:523–528.
- [46] Saiz PA, Garcia-Portilla MP, Florez G, et al. Polymorphisms of the IL-1 gene complex are associated with alcohol dependence in Spanish Caucasians: Data from an association study. *Alcohol Clin Exp Res.* **2009**;33:2147–2153.
- [47] Du J, Han JG, Zhang YJ, et al. Single-Nucleotide Polymorphisms of IL-17 Gene Are associated with Asthma Susceptibility in an Asian Population. *Med Sci Monit.* **2016**;22:780–787.
- [48] Akbulut UE, Cebi AH, Sag E, et al. Interleukin-6 and interleukin-17 gene polymorphism association with celiac disease in children. *Turk J Gastroenterol.* **2017**;28:471–475.
- [49] Zhang X, Yu P, Wang Y, et al. Genetic polymorphisms of interleukin 17A and interleukin 17F and their association with inflammatory bowel disease in a Chinese Han population. *Inflamm Res.* **2013**;62:743–750.
- [50] Heinz R, Waltenbaugh C. Ethanol consumption modifies dendritic cell antigen presentation in mice. *Alcohol Clin Exp Res.* **2007**;31:1759–1771.